Company Overview and News

0
MEP Infrastructure Developers Limited - Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

0
MEP Infrastructure Developers Limited - Shareholders meeting

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

0
MEP Infrastructure rises nearly 3% on LoA from NHAI

2018-07-06 moneycontrol
Share price of MEP Infrastructure Developers added nearly 3 percent intraday Friday as company received LoA from NHAI.
539126 MEP

0
MEP Infrastructure Developers Limited - Updates

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

1
Closing Bell: Banks, RIL lift Sensex 267 pts; Nifty ends above 10,750 despite weak Asia

2018-07-04 moneycontrol
Global Update: Asian markets ended in the red with China's Shanghai Composite losing a percent after recording gains in the previous session. Trade tensions remained in the spotlight ahead of a looming tariff deadline, reports CNBC.
BAJAJ-AUTO KOHINOOR MUTHOOTFIN BHRYY 500325 UBL RELIANCE 532978 532977 533398 SRTRANSFIN 532478 511218 532783 532187 532121 506690 534816 RIGD SRRQY HDFCBANK BJJQY INFRATEL RLNIY 500034 UNICHEMLAB INDUSINDBK UBHOLDINGS 539126 UNBWY MEP 512559 BAJAJFINSV BAJFINANCE HDB 500180 DENABANK 507458 DAAWAT

0
MEP Infra hits 52-week low after gaining 3% on signing concession agreement with NHAI for 4 projects

2018-07-04 moneycontrol
MEP Infrastructure Developers share price rallied 3 percent intraday Wednesday after signing a concession agreement for four projects with the National Highways Authority of India (NHAI), but it corrected later to hit fresh 52-week low of Rs 63.85 on the BSE.
539126 MEP

0
MEP Infrastructure Developers Limited - Updates

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

0
Sadbhav Engineering looks to raise ₹1,500 crore through QIP this quarter

2018-06-21 livemint
Mumbai: Sadbhav Engineering Ltd, a Gujarat-based infrastructure company, is looking to raise ₹1,500 crore through a qualified institutional placement (QIP) in the current quarter, said two people close to the development.
GAYAPROJ SADBHAV 539126 532767 532710 MEP

0
MEP Infrastructure Developers Limited - AGM/Book Closure

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

0
MEP Infrastructure Developers Limited - Financial Result Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

0
MEP Infrastructure Developers Limited - Outcome of Board Meeting

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

0
MEP Infrastructure Developers Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

0
MEP Infrastructure Developers Limited - Trading Window

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539126 MEP

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...